Health-care companies rose amid enthusiasm about deal activity and obesity-drug sales.

Among the companies that are involved in deals, Novartis and GSK were higher. Investors also bought into obesity-drug makers including Novo Nordisk, which is now roughly 7% higher for 2024 so far.


Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-10-24 1739ET